Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px
Document › Details

Univercells S.A.. (12/17/20). "Press Release: Univercells Holding Raises €70 Million in Series C Financing". Brussels.

Organisations Organisation Univercells S.A.
  Group Univercells (Group)
  Organisation 2 Korea Investment Partners (KIP)
Products Product contract manufacturing (biologicals)
  Product 2 venture capital
Index terms Index term Univercells–SEVERAL: investment, 202009 financing round Series C first closing €50m led by Adjuvant Capital + SFPI + SRIW
  Index term 2 Univercells–SEVERAL: investment, 202012 financing round Series C 2nd closing €20m with Soros EDF + Farallon Capital et al
Person Person Bultot, Hugues (Univercells 2013– CEO + Co-Founder)

Univercells Holding recently raises €70 million with two rounds of capital increase with new investors. The capital infusion will support the development of GMP facilities and the capacity to foster distributed manufacturing and supply of biologics.

Univercells SA recently completed their Series C second close, bringing the total raised to €70 million. The financing, which was over-subscribed, was led by institutional commitments from international funds including Adjuvant Capital and Belgian public investors SFPI (federal), SRIW (Walloon Region). The second close brings in new international investors the Soros Economic Development Fund and Farallon Capital Management another Fund from Korea Investment Partners (KIP Bio Global Fund) and a new Belgian Fund (TheClubDeal Fund).

Investment proceeds will support establishing GMP capabilities at two sites in Jumet, one dedicated to addressing manufacturing bottlenecks for pandemics, alongside new product and platform development to address key global health needs. The financing will also develop Univercells’ capacity to support distributed manufacturing and supply of biologics.

Created to make biologics available and affordable to all, Univercells is delivering on a global mission from Belgian roots. We are delighted to have further expanded the circle of shareholders to include organizations with new skills and networks to support our scale and success. Since April 2020, Univercells SA is structured as an entrepreneurial holding company with multiple affiliates – Univercells Technologies launched in February 2020 with the support of private equity fund KKR, to expand the supply of manufacturing solutions for gene therapies. A second Univercells company, Exothera, delivers bespoke process optimization and GMP clinical and commercial production of viral vectors in our Belgian sites. More Univercells’ companies are expected to formally launch in 2021.

“After the first Series-C closing of €50M, 3 months ago, I am delighted to complete this financing round with an additional €20M, bringing the funds raised this year to a total of 120€M at the level of our organization. It will help our teams to perform and accelerate the developments to achieve our global health challenges” says Hugues Bultot, CEO of Univercells.

Record changed: 2021-01-07


Picture ConsulTech GmbH RnD Credit Germany 650x80px

More documents for Univercells (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80

» top